blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4031137

EP4031137 - TREATMENT COMPRISING FXR AGONISTS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  24.03.2023
Database last updated on 08.10.2024
FormerRequest for examination was made
Status updated on  24.06.2022
FormerThe international publication has been made
Status updated on  26.03.2021
Formerunknown
Status updated on  08.10.2020
Most recent event   Tooltip24.03.2023Application deemed to be withdrawnpublished on 26.04.2023  [2023/17]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2022/30]
Inventor(s)01 / BADMAN, Michael
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139 / US
02 / BRASS, Clifford
Novartis Pharmaceuticals Corporation, One Health
Plaza
East Hanover, New Jersey 07936 / US
03 / LAFFITTE, Bryan
2540 Manchester Avenue
Cardiff, California 92007 / US
04 / KSIAZEK, Iwona
Novartis Pharma AG, Postfach
4002 Basel / CH
 [2022/30]
Representative(s)Bieri, Simona Roxana
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2022/30]
Application number, filing date20781095.318.09.2020
[2022/30]
WO2020IB58737
Priority number, dateUS201962902828P19.09.2019         Original published format: US 201962902828 P
[2022/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021053618
Date:25.03.2021
Language:EN
[2021/12]
Type: A1 Application with search report 
No.:EP4031137
Date:27.07.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 25.03.2021 takes the place of the publication of the European patent application.
[2022/30]
Search report(s)International search report - published on:EP25.03.2021
ClassificationIPC:A61K31/4436, A61K31/46, A61K31/519, A61K45/06, A61P1/16, A61P43/00, A61K9/00
[2022/30]
CPC:
A61K31/46 (EP,CN,US); A61K45/06 (EP,CN,US); A61K31/575 (US);
A61K31/4162 (US); A61K31/4436 (EP,CN); A61K31/519 (EP,CN);
A61P1/00 (CN); A61P1/16 (EP,CN); A61P43/00 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/30]
TitleGerman:BEHANDLUNG MIT FXR-AGONISTEN[2022/30]
English:TREATMENT COMPRISING FXR AGONISTS[2022/30]
French:TRAITEMENT COMPRENANT DES AGONISTES DE FXR[2022/30]
Entry into regional phase19.04.2022National basic fee paid 
19.04.2022Designation fee(s) paid 
19.04.2022Examination fee paid 
Examination procedure19.04.2022Examination requested  [2022/30]
19.04.2022Date on which the examining division has become responsible
15.11.2022Application deemed to be withdrawn, date of legal effect  [2023/17]
06.12.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time  [2023/17]
06.12.2022Despatch of communication of loss of particular rights: Claims {1}
Fees paidRenewal fee
26.08.2022Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2006044391  (INTERCEPT PHARMACEUTICALS INC [US], et al) [X] 1-8,22-28 * abstract * * paragraph [0002] - paragraph [0021] * * Examples * * claims 1-31 *;
 [X]WO2018183193  (GILEAD SCIENCES INC [US]) [X] 1-9,16-29 * abstract * * page 1, line 23 - page 2, line 16 * * page 7, line 9 - line 32 * * page 9, line 12 - line 15 * * page 10, line 22 - line 34 * * page 16, line 17 - line 18 * * examples 1,2 * * tables 1,3 * * claims 1-11 *;
 [X]WO2018191393  (GILEAD SCIENCES INC [US]) [X] 1-8,22-29 * abstract * * claims 1-31 * * examples 1-2 * * page 1, line 26 - page 2, line 17 *;
 [E]WO2020205024  (COHERUS BIOSCIENCES INC [US]) [E] 1-29 * abstract *;
 [X]  - Anonymous, "Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) - Full Text View - ClinicalTrials.gov", (20160804), URL: https://clinicaltrials.gov/ct2/show/NCT02855164, (20201113), XP055750187 [X] 1-9,12-15,22-28 * abstract *
 [X]  - KSIAZEK I ET AL, "739: FXR activation abrogates steatohepatitis, inflammation, fibrosis, metabolic syndrome, and leaky gut in newly developed dietary mouse model of nash", HEPATOLOGY; 69TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES, AASLD 2018, WILEY INTERSCIENCE, US; SAN FRANCISCO, CA, USA, vol. 68, no. Supplement 1, doi:10.1002/HEP.30257, ISSN 1527-3350, (20181001), page 440A, (20181001), XP009510969 [X] 1-29 * abstract *

DOI:   http://dx.doi.org/10.1002/hep.30257
 [X]  - NEUSCHWANDER-TETRI BRENT A ET AL, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 385, no. 9972, doi:10.1016/S0140-6736(14)61933-4, ISSN 0140-6736, (20150314), pages 956 - 965, (20141106), XP009510956 [X] 1-11,21-28 * abstract * * pagew 964, Panel, 'Interpretation' *

DOI:   http://dx.doi.org/10.1016/S0140-6736(14)61933-4
 [A]  - DAVID C. TULLY ET AL, "Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)", JOURNAL OF MEDICINAL CHEMISTRY, (20171116), vol. 60, no. 24, doi:10.1021/acs.jmedchem.7b00907, ISSN 0022-2623, pages 9960 - 9973, XP055551278 [A] 1-29 * abstract * * Tables 2-3, compound 16 * * page 9964, column 1, line 13 - line 18 * * figure 5 *

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.7b00907
 [XP]  - BERANGERE GAPP ET AL, "Farnesoid X Receptor Agonism, Acetyl-Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model", HEPATOLOGY COMMUNICATIONS, (20191108), vol. 4, no. 1, doi:10.1002/hep4.1443, ISSN 2471-254X, pages 109 - 125, XP055750153 [XP] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1002/hep4.1443
 [XP]  - M JOURDAIN ET AL, "FXR ACTIVATION BY TROPIFEXOR (TXR) RESTORES HEPATIC MITOCHONDRIAL DYSFUNCTION IN DIETARY MOUSE NASH MODEL", HEPATOLOGY, (20191001), vol. 70, no. S1, ISSN 0270-9139, page 1270A, XP055750259 [XP] 1-29 * abstract *

DOI:   http://dx.doi.org/10.1002/hep.30382
by applicantWO2012087519
 US8969557
 CN104513213
 WO2015138986
 WO2016081918
 WO2016096116
 WO2016096115
 WO2016103037
 WO2016127924
 WO2017078928
 WO2017118294
 WO2017128896
 WO2017143134
 WO2017151816
 WO2017189652
 WO2017189663
 WO2017189651
 WO2017201150
 WO2017201152
 WO2017201155
 WO2017218337
 WO2017218397
 WO2018024224
 WO2018039384
 WO2018059314
 WO2018067704
 WO2018075207
 WO2018081285
 WO2018085148
 WO2018133730
 WO2018190643
 WO2018214959
 CN109053751
 WO2019007418
    - NEVENS et al., J. Hepatol., (20140000), vol. 60, no. 1, pages 347A - 348A
    - WALTERS et al., Aliment Pharmacol. Ther., (20140000), vol. 41, no. 1, pages 54 - 64
    - TULLY et al., J Med Chem, (20170000), vol. 60, pages 9960 - 9973
    - NESS-ABRAMOF et al., Drugs of Today, (20050000), vol. 41, no. 8, pages 547 - 555
    - GRIFFITH et al., J Med Chem, (20140000), vol. 57, no. 24, pages 10512 - 26
    - LAWITZ et al., Clin Gastroenterol Hepatol, (20180000), vol. 16, no. 12, pages 1983 - 1991
    - KIM et al., Cell Metab, (20170000), vol. 26, no. 2, pages 394 - 406
    - FREEMAN-COOK et al., J Med Chem, (20120000), vol. 55, no. 2, pages 935 - 4
    - PELLICCIARI et al., J. Med. Chem., (20020000), vol. 15, no. 45, pages 3569 - 72
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.